Polio - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 49 pages report, published by Global Markets Direct

Keywords : Polio Therapeutic Products under Development, Key Players in Polio Therapeutics, Polio Pipeline Overview, Polio Pipeline, Polio Pipeline Assessment

Report ThumbnailSeptember-2013
Polio - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Polio - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Polio, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polio. Polio - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Polio.
- A review of the Polio products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Polio pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Polio.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Polio pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Polio, H2 2013 8
  • Products under Development for Polio - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Products under Investigation by Universities/Institutes, H2 2013 12
  • Late Stage Products, H2 2013 13
  • Mid Clinical Stage Products, H2 2013 14
  • Discovery and Pre-Clinical Stage Products, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 24
  • Assessment by Combination Products, H2 2013 25
  • Assessment by Route of Administration, H2 2013 26
  • Assessment by Stage and Route of Administration, H2 2013 27
  • Assessment by Molecule Type, H2 2013 28
  • Assessment by Stage and Molecule Type, H2 2013 29
  • List of Tables
  • Number of Products Under Development for Polio, H2 2013 8
  • Products under Development for Polio - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 11
  • Number of Products under Investigation by Universities/Institutes, H2 2013 12
  • Comparative Analysis by Late Stage Development, H2 2013 13
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
  • Products under Development by Companies, H2 2013 16
  • Products under Investigation by Universities/Institutes, H2 2013 17
  • Sanofi-Aventis, H2 2013 18
  • GlaxoSmithKline plc, H2 2013 19
  • Takeda Pharmaceutical Company Limited, H2 2013 20
  • Biological E. Limited, H2 2013 21
  • Panacea Biotec Limited, H2 2013 22
  • Beijing Tiantan Biological Products Co., Ltd., H2 2013 23
  • Assessment by Monotherapy Products, H2 2013 24
  • Assessment by Combination Products, H2 2013 25
  • Assessment by Stage and Route of Administration, H2 2013 27
  • Assessment by Stage and Molecule Type, H2 2013 29
  • Polio Therapeutics - Drug Profile Updates 43
  • Polio Therapeutics - Dormant Products 45
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Polio Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Polio 8
  • Polio Therapeutics under Development by Companies 10
  • Polio Therapeutics under Investigation by Universities/Institutes 12
  • Late Stage Products 13
  • Comparative Analysis 13
  • Mid Clinical Stage Products 14
  • Comparative Analysis 14
  • Discovery and Pre-Clinical Stage Products 15
  • Comparative Analysis 15
  • Polio Therapeutics - Products under Development by Companies 16
  • Polio Therapeutics - Products under Investigation by Universities/Institutes 17
  • Companies Involved in Polio Therapeutics Development 18
  • Sanofi-Aventis 18
  • GlaxoSmithKline plc 19
  • Takeda Pharmaceutical Company Limited 20
  • Biological E. Limited 21
  • Panacea Biotec Limited 22
  • Beijing Tiantan Biological Products Co., Ltd. 23
  • Polio - Therapeutics Assessment 24
  • Assessment by Monotherapy Products 24
  • Assessment by Combination Products 25
  • Assessment by Route of Administration 26
  • Assessment by Molecule Type 28
  • Drug Profiles 30
  • GSK-217744 - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • DTP-HepB-Polio-Hib - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • SP-059 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • TAK-361S - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • component pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • V-073 - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • DTwP-IPV - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • T-00127-HEV1 - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • Pentavalent DTwP-Hib-IPV Vaccine - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • Inactivated Poliomyelitis Vaccine - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • Monovalent Oral Polio Vaccine (Types 1, 2 & 3) - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • Polio Therapeutics - Drug Profile Updates 43
  • Polio Therapeutics - Dormant Products 45
  • Polio - Product Development Milestones 46
  • Featured News & Press Releases 46
  • Nov 02, 2012: GSK Announces Voluntary Recall Of Infanrix Hexa Due To Potential Contamination 46
  • Oct 11, 2012: GSK Announces Voluntary Recall Of Six Batches Of Infanrix Hexa In Australia 46
  • Nov 16, 2011: Quadrivalent Vaccine TAK-361S Enters Into Phase II Clinical Trials In Japan 46
  • Oct 26, 2000: Hexavalent pediatric vaccines licensed in EU 47
  • Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children 47
  • Appendix 48
  • Methodology 48
  • Coverage 48
  • Secondary Research 48
  • Primary Research 48
  • Expert Panel Validation 48
  • Contact Us 49
  • Disclaimer 49

Please select a license type

Share

Related Products

Global Markets DirectPolio - Pipeline Review, H2 2013Product ThumbnailPolio - Pipeline Review, H2 2013, Industry ReportProduct #: 113311
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved